TT

Tom Thomas

Senior Associate @ Newpath Partners

Boston, Massachusetts

VC
Investor

Invests in

Locations:

  • Min Investment:

    $500,000.00

  • Max Investment:

    $40,000,000.00

  • Target Investment:

    $10,000,000.00

Skills

Corporate Strategy
Project Portfolio Management
Start-up Ventures
Start-up Leadership
Early Stage Investment
New Venture Development
Healthcare Investing
Cell Culture
Molecular Biology
Genetics
Clinical Research
Research
Biochemistry
Cancer Research
Cancer
Tumor Immunology
Stem Cell Research
Cancer Stem Cells
Tissue Culture
Metabolism

Education

Work Experience

Newpath Partners

2024

  • Senior Associate

    2024

Magnet Biomedicine

2024

  • Board Observer

    2024

RA Capital Management, L.P.

2022 - 2024

  • Healthcare Associate

    2022 - 2024

Flagship Pioneering

2020 - 2022

  • Founding Team (Prologue Medicines)

    2021 - 2022

    Stealth ProtoCo, Flagship Labs 89, Inc. (FL89) - now known as Prologue Medicines

  • Associate

    2020 - 2022

  • Fellow

    2020 - 2020

Emmanuel College (Boston)

2018 - 2020

  • Adjunct Faculty of Biology

    2018 - 2020

    School of Health Sciences; Department of Biology Courses: Anatomy & Physiology, Endocrinology, Microbiology, Human Biology

Harvard Medical School

2017 - 2020

  • Research Fellow

    2017 - 2020

    Laboratory of Jon C Aster MD, PhD; Brigham & Women’s Hospital Laboratory of Stephen Blacklow MD, PhD; Harvard Medical School

Cedars-Sinai

2013 - 2017

  • Ph.D Candidate, Cancer Biology

    2013 - 2017

    Laboratory of John S. Yu MD; Maxine Dunitz Neurosurgical Institute

University of California, Los Angeles

2008 - 2011

  • Research Associate

    2008 - 2011

    Laboratory of Jake Lusis, PhD; Department of Molecular Genetics

Scripps Research

2005 - 2006

  • Research Intern

    2005 - 2006

    Laboratory of Thomas J. Kunicki, PhD; Department of Molecular & Experimental Medicine